MARKET

XFOR

XFOR

X4 Pharmaceuticals Inc
NASDAQ
3.100
-0.130
-4.02%
After Hours: 3.050 -0.05 -1.61% 17:11 05/23 EDT
OPEN
3.260
PREV CLOSE
3.230
HIGH
3.260
LOW
3.001
VOLUME
168.08K
TURNOVER
--
52 WEEK HIGH
33.90
52 WEEK LOW
2.670
MARKET CAP
17.94M
P/E (TTM)
1.381
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XFOR last week (0512-0516)?
Weekly Report · 4d ago
X4 PHARMACEUTICALS ANNOUNCES UPCOMING PRESENTATION OF PHASE 2 CHRONIC NEUTROPENIA TRIAL DATA AT THE 30TH ANNUAL EHA CONGRESS
Reuters · 05/14 20:12
Weekly Report: what happened at XFOR last week (0505-0509)?
Weekly Report · 05/12 09:43
Healthcare stocks that could be poised for a rebound
Seeking Alpha · 05/09 16:31
Weekly Report: what happened at XFOR last week (0428-0502)?
Weekly Report · 05/05 09:43
X4 Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 05/02 16:08
X4 Pharmaceuticals Price Target Raised to $7.00/Share From $1.50 by HC Wainwright & Co.
Dow Jones · 05/02 12:57
X4 Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 05/02 12:57
More
About XFOR
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Webull offers X4 Pharmaceuticals Inc stock information, including NASDAQ: XFOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XFOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XFOR stock methods without spending real money on the virtual paper trading platform.